Related Experiment Video
Updated: Jul 8, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Implications of different DCCT-aligned HbA1c methods on GMS clinical indicators
P J Twomey1, G Rayman, D R Pledger
1Department of Clinical Biochemistry, The Ipswich Hospital, Ipswich, UK. ptwomey@nhs.net
Diabetic Medicine : a Journal of the British Diabetic Association
|January 18, 2008
Summary
Different glycated haemoglobin (HbA1c) testing methods impact diabetes management under UK General Medical Services (GMS) contracts. Understanding these HbA1c method limitations is crucial for healthcare professionals and policymakers.
Area of Science:
- Clinical Chemistry
- Diabetes Mellitus Management
- Health Policy
Background:
- The UK General Medical Services (GMS) contract incentivizes diabetes care, including glycated haemoglobin (HbA1c) testing.
- Specific codes (DM5-DM7) focus on HbA1c targets, contributing significantly to practice income.
- Variability in HbA1c testing methods may affect achievement of treatment targets.
Purpose of the Study:
- To compare two routinely used Diabetes Control and Complications Trial (DCCT)-aligned HbA1c methods.
- To assess if differences in HbA1c assay results could lead to variations in achieving treatment targets across UK general practices.
Main Methods:
- A comparative analysis of two HbA1c testing platforms: DCA 2000+ Analyser and Variant II analyser.
- 164 patient samples were randomly selected and analyzed on both devices.
Main Results:
- A statistically significant difference (P < 10(-09)) was observed between the two HbA1c methods.
- Despite a small mean difference (6.5%), the methods classified 18.9% of patients (31 individuals) differently regarding the DM6 GMS target (HbA1c ≤ 7.4%).
- The DCA 2000+ Analyser identified more patients below the target (38.4%) compared to the Variant II analyser (19.5%).
Conclusions:
- While DCCT-alignment has improved HbA1c value transferability, it has not eliminated method-dependent discrepancies.
- Healthcare professionals and policymakers must be aware of the limitations of current DCCT-aligned HbA1c assays.
- These limitations have potential financial and clinical implications for diabetes care delivery and performance monitoring.
Related Concept Videos
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...